Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV...( - Not Intended for Journa...),Health

- Not Intended for Journalists in the UK or Ireland - New Findings From ARTEMIS and TITAN Studies Demonstrate Growth of the

Tibotec Virology Franchise

GLASGOW, Scotland, Nov. 12 /PRNewswire/ -- New data on PREZISTA(R) (darunavir), a protease inhibitor from Tibotec, will be presented at the Ninth International Congress on Drug Therapy in HIV Infection (HIV9) in Glasgow, U.K., from 09-13 November 2008. The company also presented new data on PREZISTA(R) at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C., from 25-28 October 2008. These presentations follow key regulatory approvals and decisions for PREZISTA(R) and INTELENCE(TM) (etravirine), a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). The company continues to research various compounds in hepatitis C, tuberculosis and HIV.

"The Tibotec data being presented at HIV9 culminate an exciting three months for the company and for the entire HIV community," said Roger Pomerantz, President, Tibotec Research & Development. "The data we've amassed and the regulatory milestones we've achieved this year are signs of our dedication to finding innovative ways to meet the needs of people with HIV."

Recent Regulatory Milestones for Tibotec in HIV

- 28 August 2008 - The European Commission approved etravirine, in

combination with a boosted protease inhibitor and other antiretroviral

medicinal products, for the treatment of human immunodeficiency virus

type 1 (HIV-1) infection in antiretroviral treatment-experienced adult

patients.

- 21 October 2008 - The U.S. FDA granted traditional approval to

darunavir, coadministered with low dose ritonavir, for twice-daily use

in treatment-experienced adult patients, as well as an expanded

indication for once-daily dosing as part of HIV combination therapy in

treatment-na
'/>"/>